Zentalis Pharmaceuticals Inc at Morgan Stanley Global Healthcare Conference Transcript
Good morning, everyone. Thanks for joining us on day 3 of the Morgan Stanley Global Healthcare Conference. I'm Mike Ulz, for the biotech analyst here, and it's my pleasure to introduce Kim Blackwell, CEO of Zentalis Pharmaceuticals. Just a reminder for today, the format is a fireside chat. But before we get started, I just need to read a quick disclosure statement. For important disclosures, please see the Morgan Stanley research disclosure website at www.morganstanley.com/researchdisclosures. If you have any questions, please reach out to your Morgan Stanley sales representative.
And with that, Ken, thanks for joining us today. And maybe I can just turn it over to you for some brief background on Zentalis, and then we can get into some Q&A.
Sure. Well, thanks for having me. For those of you who are brand new to the
Access to All Earning Calls and Stock Analysis | |
30-Year Financial on one screen | |
All-in-one Stock Screener with unlimited filters | |
Customizable Stock Dashboard | |
Real Time Insider Trading Transactions | |
8,000+ Institutional investors’ 13F holdings | |
Powerful Excel Add-in and Google sheets Add-on | |
All data downloadable | |
Quick customer support | |
And much more... |